ArticleFrontiers in cellular neuroscience2025
AhR regulation of amyloid beta-induced inflammation in astrocyte cells.
Article in Frontiers in cellular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut-derived memory T cells: key mediators of neuroinflammation via the gut-brain axis.Frontiers in medicine · 2026Review
- The aryl hydrocarbon receptor is expressed in non-sensory cells in the cochlea and regulates hair cell survival.Frontiers in molecular neuroscience · 2026Article
- Aryl hydrocarbon receptor deficiency enhances astrocyte sensitivity to LPS-induced inflammation.Frontiers in cellular neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Amyloid beta (Aβ) plaques, tau tangles, and neuroinflammation are common features present in Alzheimer's Disease (AD), and glial cells are essential mediators of the inflammatory reaction. Aryl hydrocarbon receptor (AhR), a transcription factor engaged in regulation of immune function, may be involved in the pathogenesis of AD, through modulation of neuroinflammation. This study explores how AhR affects astrocyte function in response to inflammatory stimuli, with emphasis on Aβ. Methods and Results: In primary hippocampal astrocyte cultures from wild type (WT, C57BL6/J) or AhR germline knockout (AhRKO) mice, pretreatment with the AhR agonist, 6-Formylindolo[3,2-b] carbazole (FICZ), attenuated Aβ-induction of reactive astrocyte development, characterized by decreased astrocyte complement C3 expression and decreased proinflammatory cytokine release. In addition, Aβ exposure exacerbated TNF-a cytokine release and increased GFAP immunoreactivity in astrocytes derived from AhRKO mice. In response to Aβ injection into the mouse hippocampus Discussion: These findings suggest that AhR activation in astrocytes attenuates development of the neuroinflammatory state, and identifies AhR as an interesting therapeutic target to mitigate neuroinflammation and the progression of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.